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To investigate the exact isolation frequency of 16S
rRNA methylase–producing, gram-negative pathogenic
bacteria, we tested 87,626 clinical isolates from 169 hospi-
tals. Twenty-six strains from 16 hospitals harbored 16S
rRNA methylase genes, which suggests sparse but diffuse
spread of pan-aminoglycoside–resistant microbes in
Japan.
B
road-spectrum β-lactams and fluoroquinolones have
been widely prescribed in the treatment of gram-neg-
ative bacterial infections; as a result, resistance to these
antimicrobial agents has developed in some species.
Although these agents are not immune to an increasing
number of resistance mechanisms, they remain relatively
potent and continue to be essential antimicrobial drugs for
treating life-threatening bacterial infections.
Although the production of aminoglycoside-modify-
ing enzymes is the most common mechanism of resistance
in aminoglycosides, the emergence of pan-aminoglyco-
side–resistant, 16S rRNA methylase–producing, gram-
negative bacteria has been increasingly reported in recent
years. Five types of plasmid-mediated 16S rRNA methy-
lases (ArmA, RmtA, RmtB, RmtC, and RmtD) have so far
been identified in east Asia, Europe, and South America
(1–7). RmtA was first identified in 2001 in Japan (3) and
has so far been identified exclusively in Pseudomonas
aeruginosa (8). RmtC was subsequently identified only in
Proteus mirabilis (4). RmtB has been found among various
gram-negative bacterial species, including Serratia
marcescens,  Escherichia coli,  Citrobacter freundii,
Klebsiella pneumoniae, and Klebsiella oxytoca, isolated in
Japan, South Korea, and Taiwan (2,5,6,9). Another new
16S rRNA methylase was initially identified in C. freundii
in Poland, submitted to European Molecular Biology
Laboratory (EMBL)/GenBank in 2002 (accession no.
AF550415), and later characterized and assigned as ArmA
in  K. pneumoniae,  E. coli,  Enterobacter cloacae,
Salmonella enterica, and Shigella flexneri in France,
Bulgaria, and Spain (10,11). Moreover, ArmA was also
identified in E. coli, K. pneumoniae, E. cloacae, C. fre-
undii and  S. marcescens in South Korea, Japan, and
Taiwan (5,8,9). This enzyme has also been identified in a
glucose nonfermentative Acinetobacter sp. in South Korea
and Japan (6,8). Quite recently, RmtD was newly identi-
fied in the SPM-1–producing P. aeruginosa strain PA0905,
which was isolated in Brazil (7). In Japan, arbekacin, a
semisynthetic aminoglycoside, has been approved for
treatment of methicillin-resistant Staphylococcus aureus
infections, and this agent is also very efficacious for gram-
negative bacteria. However, 16S rRNAmethylase–produc-
ing microbes can adapt to this agent, and its prescription
may well be a selective pressure on the kind of microbes in
the clinical environment. Thus, this investigation was con-
ducted to determine the exact isolation frequency of 16S
rRNA methylase–producing, gram-negative pathogenic
bacteria in Japanese medical facilities and assess the pos-
sibility of the future prevalence of these hazardous
microbes.
The Study
From September 1 to October 31, 2004, 169 medical
facilities with in-house microbiology laboratories partici-
pated in this investigation. Clinical specimens were col-
lected from inpatients and outpatients with suspected
infections. Bacterial isolates that belonged to the family
Enterobacteriaceae or were nonfermentors of glucose, for
example,  P.  aeruginosa and  Acinetobacter spp., were
included in this study. A total of 87,626 clinical isolates
were analyzed. The results are shown in Table 1.
Twenty-nine strains (17 P. aeruginosa, 4 A. bauman-
nii, 3 E. coli, 2 P. mirabilis, 1 E. cloacae, 1 K. pneumoni-
ae, and 1 Enterobacter aerogenes) that grew on LB agar
plates supplemented with 500 mg of arbekacin per liter
were subjected to the typing of 16S rRNAmethylase genes
by a multiplex PCR. Primers used for the PCR amplifica-
tion of bacterial 16S rRNA methylase genes were the fol-
lowing: RMTA-F 5′-CTAGCG TCC ATC CTTTCC TC-3′
and RMTA-R 5′-TTT GCT TCC ATG CCC TTG CC-3′,
which amplify a 635-bp DNA fragment within rmtA gene
(3); RMTB-F 5′-GCT TTC TGC GGG CGA TGT AA-3′
and RMTB-R 5′-ATG CAA TGC CGC GCT CGT AT-3′,
which amplify a 173-bp DNA fragment within rmtB (2);
RMTC-F 5′-CGAAGAAGT AAC AGC CAAAG-3′ and
RMTC-R 5′-ATC CCAACATCT CTC CCACT-3′, which
amplify a 711-bp DNA fragment within rmtC (4); and
ARMA-F 5′-ATT CTG CCT ATC CTA ATT GG-3′ and
ARMA-R 5′-ACC TATACTTTATCG TCG TC-3′, which
amplify a 315-bp DNA fragment within armA (accession
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*National Institute of Infectious Diseases, Tokyo, Japannos. AY220558 and AB117519). PCR results and clinical
data from these 29 strains are summarized in the Table 2.
Genes for 16S rRNA methylases were absent in 3
arbekacin high-level-resistant strains of P. aeruginosa by
PCR analyses that used 4 sets of 16S rRNAmethylase-spe-
cific primers. In these strains, simultaneous production of
multiple aminoglycoside-modifying enzymes was suggest-
ed as reported previously (12). Twenty-six strains harbor-
ing any of the four 16S rRNA methylase genes were
identified in 16 hospitals, with no apparent geographic
convergence in the locations of the hospitals (Figure 1). In
hospital L, 3 different bacterial species (E. coli, E. aero-
genes, and K. pneumoniae) harbored the armA gene, which
suggests probable conjugal transfer of armA-carrying plas-
mids among different bacterial species.
Pulsed-field gel electrophoresis (PFGE) was per-
formed on 9 strains of P. aeruginosa and 3 strains of A.
baumannii isolated from 4 separate hospitals where 16S
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DNA preparations from P. aeruginosa and A. baumannii
were digested with SpeI and SmaI, respectively. Clonality
was inferred based on the criteria of Tenover et al. (13)
Two of 3 rmtA-positive P. aeruginosa strains isolated in
hospital C were estimated to be the same clone. Among 4
rmtA-positive P. aeruginosa isolates recovered in hospital
D, 2 different clonal lineages were observed. This finding
suggests possible conjugal transfers of rmtA-carrying plas-
mids among genetically different strains of P. aeruginosa.
Three  armA gene–harboring  A. baumannii identified in
hospital S were obviously the same clone. These findings
imply probable nosocomial transmission of 16S rRNA
methylase gene–harboring strains in hospitals C, D, and S,
as well as frequent conjugal transfers of plasmids carrying
16S rRNA methylase genes among gram-negative patho-
genic bacterial species.
MIC determinations were performed according to the
guideline of the CLSI (formerly National Committee on
Clinical Laboratory Standards). All 16S rRNA methylase-
positive strains were highly resistant (MICs >1,024 mg/L)
of all 4,6-disubstituted deoxystreptamine group aminogly-
cosides (Table 3). In contrast, resistance to streptomycin
and neomycin varied. Three16S rRNA methylase gene-
negative P. aeruginosa strains were also highly resistant to
arbekacin, but the MICs of some of the 4,6-disubstituted
deoxystreptamine group aminoglycosides were relatively
lower (256–512 mg/L) for these strains than those for 16S
rRNA methylase gene–positive strains (>1,024 mg/L).
Strains harboring 16S rRNA methylase genes tended to
show resistance to oxyimino-cephalosporins such as cefo-
taxime and ceftazidime as well, but were susceptible to
imipenem. As reported for the armA- or rmtB-bearing
strains, the presence of β-lactamase genes was suggested
in cefotaxime-resistant strains, and indeed the blaCTX-M-14
gene was detected in several rmtB-positive strains tested in
our study (data not shown). Some of these strains also
demonstrated resistance to fluoroquinolones (Table 3).
Conclusions
The overall isolation frequency of 16S rRNA methy-
lase-gene-positive gram-negative bacilli was very low
(0.03%) in Japanese medical facilities in 2004, with the
highest rates seen in P. aeruginosa and Acinetobacter spp.
at 0.08% and 0.13%, respectively. Twenty-six bacterial
isolates carrying 1 of the four 16S rRNA methylase genes
were recovered from 16 (9.5%) of 169 hospitals that par-
ticipated in this nationwide investigation. Of the 169 hos-
pitals, 162 hospitals had >200 beds, accounting for 5.9%
of all Japanese hospitals of similar scale. This implies that
16S rRNA methylase–producing strains might have been
present in >250 Japanese hospitals during the investigation
period, which in turn suggests sparse but diffuse spread of
16S rRNA methylase producers in Japan. Since several
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Figure 1. Geographic distribution of hospitals where 16S rRNA
methylase gene-positive strains were isolated. Of 16 hospitals, 4
were located in the Kanto area (Gunma and Tokyo), 6 in the Chubu
area (Aichi, Gifu, and Shizuoka), 1 in the Koushin-etsu area
(Nagano), 4 in the Kinki area (Osaka, Nara, and Hyogo), and 1 in
the Kyushu area (Miyazaki). This distribution suggests a sparse but
diffuse spread of 16S rRNA methylase-producing, gram-negative
pathogenic microbes in Japan. Bacterial species and type of 16S
rRNA methylase identified in each hospital are shown in Table 2.
Figure 2. A) Pulsed-field gel electrophoresis (PFGE) fingerprinting
patterns of SpeI-digested total DNA preparations from
Pseudomonas aeruginosa. M, Lambda ladder PFGE molecular
mass marker (Bio-Rad, Hercules, CA, USA). Strains 103 and 109
show similar patterns, which suggests probable nosocomial trans-
mission of rmtA-positive strains in hospital C. Strains 113, 127, and
158 also demonstrate similar patterns, which implies possible
nosocomial transmission in hospital D. However, 2 different PFGE
patterns are observed in hospitals C, D, and F, which suggests
transfer of plasmids carrying 16S rRNA-methylase genes among
P. aeruginosa strains with different genetic backgrounds. B) SmaI-
digested total DNA preparations from Acinetobacter baumannii
isolated from hospital S. Three strains demonstrate the same
PFGE pattern, which suggests probable nosocomial transmission
of armA-positive A. baumannii in hospital S. M, lambda ladder low-
range PFGE molecular mass marker (New England Biolabs,
Ipswich, MA, USA).armA- or rmtB-positive strains have also been isolated in
European and Asian countries, and given the potential for
further dissemination, nationwide identification and ongo-
ing surveillance of these isolates should be considered by
all countries.
According to PFGE typing, nosocomial transmission
of 16S rRNA methylase–producing P. aeruginosa and A.
baumannii was suspected in 3 hospitals (hospitals C, D, and
S). The banding patterns of rmtA-harboring P. aeruginosa
isolated in hospitals C, D, and F were diverse, which
excluded the possibility of an epidemic P. aeruginosa strain
harboring the rmtA gene. Despite the observation of 2 dif-
ferent PFGE profiles among the 4 P. aeruginosa strains iso-
lated in hospital D, they might share the same plasmids
carrying the rmtA gene. For further characterization of
genetic relations among rmtA-harboring  P.  aeruginosa
strains, comparative analyses of plasmids and mobile ele-
ments that carry the rmtA gene (14) should also be pursued.
Nosocomial infections caused by multidrug-resistant,
gram-negative bacteria have become a serious problem in
clinical facilities. P. aeruginosa and  Acinetobacter spp.
have been especially efficient at developing multidrug
resistance against broad-spectrum β-lactams, fluoro-
quinolones, and aminoglycosides (3,6,7,9). The identifica-
tion of armA and rmtB genes in Europe and East Asia in
both human (1–11) and livestock (15;  EMBL/GenBank
accession no. DQ345788) populations suggests that we
must pay consistent attention to prevent further global pro-
liferation. If 16S rRNA methylase–positive bacterial iso-
lates disseminate widely and extensively, the high level of
pan-aminoglycoside resistance will undoubtedly have an
impact on illness, deaths, and costs of care in both clinical
and livestock-breeding environments.
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